New avenues in pancreatic cancer: exploiting microRNAs as predictive biomarkers and new approaches to target aberrant metabolism

Capula, Mjriam; Mantini, G.; Funel, Niccola; Giovannetti, Elisa

doi:10.1080/17512433.2019.1693256

Cited by 24 publications

(14 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These serum ex-miRNAs may be used as non-invasive, specific and sensitive biomarkers for the diagnosis and prognosis of tumors (42). Alterations of circulating miRNAs have been investigated in patients with PC (43). However, studies on serum ex-miRNAs in PC are lacking.…”

Section: Discussionmentioning

confidence: 99%

Circulating exosomal microRNAs as novel potential detection biomarkers in pancreatic cancer

Zhou

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Circulating exosomal microRNAs (ex-miRNAs) are reflective of the characteristics of the tumor and are valuable biomarkers in different types of tumor. In addition, miRNAs serve important roles in tumor progression and metastasis. The present study aimed to investigate the circulating ex-miRNA-21 and miRNA-210 as novel biomarkers for patients with pancreatic cancer (PC). For this purpose, serum ex-miRNAs were extracted from the serum of patients with PC (n=30) and chronic pancreatitis (CP) (n=10) using an RNA isolation kit. For exosome identification in serum, transmission electron micrographs were used to determine crystalline structure, western blotting was used to identify exosomal markers, and NanoSight was used for nanoparticle characterization. The relative expression levels of ex-miRNAs were quantified using quantitative PCR and compared between patients with PC and CP. The expression levels of both ex-miRNA-21 and miRNA-210 were significantly higher in patients with PC compared with patients with CP (both P<0.001). However, no significant difference in the relative serum levels of free miR-21 and miR-210 was observed between the 2 groups of patients (both P>0.05). ex-miRNA-21 and miRNA-210 were associated with tumor stage, as well as other factors. The diagnostic potential of ex-miRNA-21 and miRNA-210 levels was 83 and 85%, respectively. In addition, when ex-miRNA and serum carbohydrate antigen 19-9 expression levels were combined, the accuracy increased to 90%. The present study identified that serum ex-miRNAs, miRNA-21 and miRNA-210 may be of value as potential biomarkers and therapeutic targets for the diagnosis and treatment of PC.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating exosomal microRNAs as novel potential detection biomarkers in pancreatic cancer

Zhou

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Tumor biomarkers are the molecular indicators found in blood, other body fluids, or on tissues that can be interrogated to evaluate disease status and pharmacologic responses to therapeutic interventions. Biomarkers include RNAs (Capula et al 2019 ; Funamizu et al 2019 ), hormones (Costante and Meringolo 2020 ; Riccetti et al 2017 ), as well as different functional subgroups of proteins such as enzymes (Miao et al 2013 ), glycoproteins (Luo et al 2018 ), oncofetal antigens (Feng et al 2017 ) and receptors. Selected targeting peptides are currently used as biomarkers for some cancers with high incidence (Luna Coronell et al 2012 ).…”

Section: Potential Applications Of Targeting Peptidesmentioning

confidence: 99%

Application of Phage-Displayed Peptides in Tumor Imaging Diagnosis and Targeting Therapy

Xü

et al. 2020

Int J Pept Res Ther

View full text Add to dashboard Cite

Phage display is an effective and powerful technique that provides a route to discovery unique peptides targeting to tumor cells. Specifically binding peptides are considered as the valuable target directing molecule fragments with potential efficiency to improve the current tumor clinic, and offer new approaches for tumor prevention, diagnosis and treatment. We focus on the recent advances in the isolation of tumor-targeting peptides by biopanning methods, with particular emphasis on molecular imaging, and pharmaceutical targeting therapy.

show abstract

“… 7 Different miRNA expression profiles are present at different stages of pancreatic malignancy and expected to be used as prognostic markers, clinical targets and individualized therapy. 8 miRNAs can complement the 3ʹ -untranslated region (3ʹ-UTR) of their target mRNA sequence to induce mRNA degradation or translation inhibition, thereby regulating gene expression. 9 The analysis of miRNAs combined with mRNAs is crucial to better understand and predict the role of miRNAs in regulating gene expression.…”

Section: Introductionmentioning

confidence: 99%

A Novel miRNA–mRNA Axis Involves in Regulating Transcriptional Disorders in Pancreatic Adenocarcinoma

Shang¹,

Shi²,

Taule³

et al. 2021

CMAR

View full text Add to dashboard Cite

Background Currently, there is still a lack of understanding about the mechanism and therapeutic targets of pancreatic adenocarcinoma (PAAD). The potential of miRNA–mRNA networks for the identification of regulatory mechanisms involved in PAAD development remains unexplored. Methods We compared differentially expressed miRNAs (DEMIs) and differentially expressed genes (DEGs) in PAAD and normal tissues from the Gene Expression Omnibus (GEO) database. Transcription factors (TFs) were obtained from FunRich. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of DEGs and DEMIs were implemented using Database for Annotation, Visualization and Integrated Discovery (DAVID). Then, key miRNAs and targeted mRNAs were identified by assessment of their expression and prognosis in UALCAN and Kaplan–Meier plotters. In the last step, the candidate miRNA–mRNA selected was confirmed by real-time quantitative polymerase chain reaction (qRT-PCR). Results We distinguished 62 significant DEMIs, 1314 upregulated DEGs, and 1110 downregulated DEGs. The top 10 TFs were identified. In total, there were 160 hub genes obtained by intersecting the set of 2224 predicted targets with the set of significant DEGs. And we selected 8 key miRNAs. Furthermore, low expression of miR-455-3p in PAAD tissue was closely connected with poor prognosis, and only 5 target mRNAs were predicted to be increased in PAAD tissue with poor prognosis. Therefore, a novel miRNA–hub gene regulatory network in PAAD was constructed. Finally, in vitro experiments indicated that miR-455-3p expression was decreased in PAAD sample. HOXC4, DLG4, DYNLL1 and FBXO45 were validated by qRT-PCR as highly probable targets of miR-455-3p. Conclusion A novel miRNA–mRNA axis has been discovered that may be involved in the regulation of transcriptional disorders and affected the survival of PAAD patients, which would provide a novel strategy for the treatment of PAAD.

show abstract

New avenues in pancreatic cancer: exploiting microRNAs as predictive biomarkers and new approaches to target aberrant metabolism

Cited by 24 publications

References 96 publications

Circulating exosomal microRNAs as novel potential detection biomarkers in pancreatic cancer

Circulating exosomal microRNAs as novel potential detection biomarkers in pancreatic cancer

Application of Phage-Displayed Peptides in Tumor Imaging Diagnosis and Targeting Therapy

A Novel miRNA–mRNA Axis Involves in Regulating Transcriptional Disorders in Pancreatic Adenocarcinoma

Contact Info

Product

Resources

About